Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 10« First...34567...10...Last »

Trump’s drug czar nominee withdraws from consideration

President Donald Trump’s pick for U.S. drug czar withdrew after it become public that he spearheaded a bill that undercut the government’s power to crack down on opioid makers that were flooding the market with the addictive painkillers.

Read More »

Amneal, Impax to combine in generics push

Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc. in an all-stock deal as the company looks to add heft to its generics business.

Read More »

New cancer drugs help J&J top profit estimates

Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.

Read More »

Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumors

An experimental cancer drug discovered by Hutchison China MediTech demonstrated promising activity in shrinking tumors in lung cancer patients whose disease had worsened following treatment with approved medicines.

Read More »

Pfizer Touts Lung Cancer, Brain Tumor Data

Mid-stage data shows that Pfizer’s lorlatinib could provide benefits to lung cancer patients who exhibit related brain tumors.

Read More »

Exelixis Cancer Drug Meets Goals in Phase III Trial

Exelixis’s Cabometyx (cabozantinib) hit key endpoints of overall survival in its Phase III liver cancer trial.

Read More »

Incyte Claims Flexus Lured Away CSO and Its IDO Secrets, Then Sold Itself to Bristol-Myers in $1.25B Deal

Incyte leveled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former chief scientific officer who had access to Incyte’s scientific research.

Read More »

Warp Drive Bio Scores $387M R&D Pact With Roche

Through a strategic collaboration deal with Roche, Warp Drive Bio will use its Genome Mining Platform to investigate potential antibiotics for drug-resistant Gram-negative bacteria.

Read More »

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics said on Monday it would collaborate with Regeneron Pharmaceuticals and Sanofi to develop its experimental peanut allergy drug.

Read More »

BrainStorm enrolls first patients in advanced ALS stem cell trial

BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

Read More »

U.S. states sue to block Trump Obamacare subsidies cut

Eighteen U.S. states sued President Donald Trump’s administration to stop him from scrapping a key component of Obamacare, subsidies to insurers that help millions of low-income people pay medical expenses, even as Trump invited Democratic leaders to negotiate a deal.

Read More »

Alecensa wins EU panel’s nod against lung cancer

Swiss drugmaker Roche’s Alecensa was recommended for approval in Europe as a first-line treatment for mutated lung cancer.

Read More »

CHMP Issues a Positive Opinion on Janssen’s Zytiga to Include Earlier Stage Prostate Cancer Patients

Janssen-Cilag International NV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended broadening the existing marketing authorization for Zytiga (abiraterone acetate) plus prednisone/prednisolone to include an earlier stage of prostate cancer than its current indications.

Read More »

FDA Responds to Antares Pharma’s Xyosted NDA

The U.S. FDA identified unnamed deficiencies in Antares Pharma’s NDA for Xyosted that halted discussion of labeling and postmarketing requirements.

Read More »

Massachusetts’ Biostage Slashes 71 Percent of Staff, Evaluating Strategic Alternatives

An investor decision to renege on acquiring more than $3 million worth of stock has created a financial catastrophe for Biostage Inc. To maintain operations, the company is terminating 17 employees, about 71 percent of its workforce.

Read More »

Trump scraps key Obamacare subsidies, urges Democrats to fix ‘broken mess’

President Donald Trump urged Democrats to make a deal with him on healthcare after he scrapped billions of dollars in Obamacare subsidies to private health insurers for low-income Americans in a move that raised concerns about chaos in insurance markets and could face legal challenges.

Read More »

Allergan settles with one of four companies contesting Restasis patent

Allergan Plc said it reached a settlement with InnoPharma Inc., one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

Read More »

FDA panel backs gene therapy for rare blindness form

Spark Therapeutics Inc.’s experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded, paving the way for the first U.S. gene therapy for an inherited disease.

Read More »

NIH partners 11 drugmakers to accelerate cancer therapy research

The National Institutes of Health said it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body’s immune system to fight cancer.

Read More »

FDA rejects AcelRx Pharma’s opioid painkiller

Shares of AcelRx Pharmaceuticals plunged more than 60 percent after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

Read More »

Page 5 of 10« First...34567...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom